MOTS-c and SS-31 are both mitochondria-derived peptides (MDPs) with emerging therapeutic potential, primarily targeting mitochondrial function. MOTS-c, based on studies in our corpus, is linked to metabolic regulation and shows promise as a biomarker for metabolic dysfunction, liver fibrosis, and cardiovascular risk in specific patient populations like those with kidney disease. SS-31 (Elamipretide), in the studies indexed here, has been explored for its potential in treating vision loss in Friedreich Ataxia and improving cardiac function in Barth Syndrome, suggesting a focus on mitochondrial dysfunction in rare genetic conditions and specific organ systems.
| MOTS-c | SS-31 | |
|---|---|---|
| Drug class | mitochondrial peptide | mitochondrial peptide |
| Studies in corpus | 108 | 86 |
| Highest evidence tier | meta analysis | cohort |
| Evidence tier mix | other · 36 review · 9 cohort · 6 preclinical animal · 37 in vitro · 8 meta analysis · 1 | preclinical animal · 37 review · 15 other · 14 cohort · 1 in vitro · 14 case report · 1 case series · 1 |
| Studies with explicit sample size | 1 | 1 |
| Head-to-head studies in corpus | 3 | |
Studies in our corpus that mention both MOTS-c and SS-31 — the gold-standard direct comparison evidence.
The findings underscore the significant therapeutic potential of mitochondrial-derived peptides as a novel class of agents for preventing and treating vascular aging and associated cardiovascular diseases. By targeting fundamental cellular processes like mi…
This review significantly advances our understanding of mitochondria-derived peptides (MDPs) as critical regulators of hepatic metabolism and potential therapeutic agents. The identification of MDPs like MOTS-c and Humanin as key players in combating liver …
This review underscores the immense therapeutic potential of mitochondria-derived peptides as a novel class of agents for treating cardiovascular diseases. By directly targeting mitochondrial dysfunction, MDPs offer a unique approach to not only manage symp…
No direct head-to-head trials in our corpus. Indirect comparison only. While both are MDPs, their specific applications and the nature of the supporting evidence in our corpus show some divergence. MOTS-c has been investigated through cohort studies and systematic reviews, linking its circulating levels to metabolic health, liver fibrosis in MAFLD, and as a predictor of mortality and cardiovascular events in dialysis patients. This suggests a role as both a potential therapeutic target and a biomarker for risk stratification in broader metabolic and cardiovascular contexts. SS-31, also known as Elamipretide, has been explored in pilot studies and case reports for more specific, often rare, conditions. For instance, a pilot study targeted vision loss in Friedreich Ataxia, and a case report suggested its promise for Barth Syndrome, directly addressing mitochondrial dysfunction in these genetic heart conditions. The evidence for SS-31 in our corpus is primarily from case series and reports, indicating an earlier stage of clinical investigation for these specific applications compared to the broader observational and meta-analysis data available for MOTS-c's biomarker potential.
Looking for vendor-level purity, endotoxin, and HPLC data on MOTS-c or SS-31? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.